Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ACADEMIA
ACADEMIA
- Univ. of Tokyo Starts Testing Avigan Plus Futhan for COVID-19
May 11, 2020
- 5-Year Cancer Survival Rates Up 2 Points to 64.1%: NCC
April 17, 2020
- Gunma Univ. Hospital Plans Clinical Research Covering Hydroxychloroquine
April 13, 2020
- BCG’s Efficacy in COVID-19 Not Yet Confirmed: Japan Vaccine Society
April 6, 2020
- Researchers Unlock SAL Inhibitory Mechanism of Obesity Med Orlistat; Potential Treatment for MRSA/Atopic Dermatitis
March 30, 2020
- Otsuka, NCC Develop Comprehensive Genomic Profiling Assay for Blood Cancer
March 27, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- COVID-19 Patients in Japan Improved on Plaquenil
March 11, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
- Kyoto Univ., NTT Launch New Company to Analyze, Provide RWD; Label Expansions Eyed for Cancer Drugs
February 5, 2020
- TMDU Research Team Calls for New Hypothesis on Cause of AD; Could Lead to Development of Gene Therapy
January 28, 2020
- Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
January 20, 2020
- Nagasaki Univ., Kobe Foundation Tie Up on Clinical Development
January 17, 2020
- Impact of Oligonucleotides - 2: Expert Says Spinraza Changed SMA Treatment Paradigm, Has High Expectation for Zolgensma Too
January 17, 2020
- Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain
January 16, 2020
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…